| Previous close | 27.70 |
| Open | 0.00 |
| Bid | 26.70 x N/A |
| Ask | 29.30 x N/A |
| Day's range | 27.99 - 27.99 |
| 52-week range | 25.21 - 37.80 |
| Volume | |
| Avg. volume | 98,877 |
| Market cap | 169.64B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 7.44 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.64 (5.31%) |
| Ex-dividend date | 08 Nov 2023 |
| 1y target est | N/A |
- Business Wire
Cyrus Taraporevala Elected to Pfizer’s Board of Directors
NEW YORK, July 01, 2024--Pfizer Inc. (NYSE: PFE) today announced the election of Cyrus Taraporevala to its Board of Directors, effective immediately. Mr. Taraporevala, age 57, was also appointed to and will join the Audit Committee and Compensation Committee of Pfizer’s Board.
- Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany, June 27, 2024--Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron JN.1-adapted monovalent COVID-19 vaccine (COMIRNATY® JN.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the
- Business Wire
Pfizer Declares Third-Quarter 2024 Dividend
NEW YORK, June 26, 2024--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 third-quarter 2024 dividend on the company’s common stock, payable September 3, 2024, to holders of the Common Stock of record at the close of business on July 26, 2024. The third-quarter 2024 cash dividend will be the 343rd consecutive quarterly dividend paid by Pfizer.
